Francisco Marrero, MD
Gastroenterology · Lake Charles, LANPI 1093705055
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,744 of the $83,730 with a category attached, or 89.3%. 30 manufacturers reported payments, led by AbbVie at 53.7% of the total. 2025 is the largest year on record at $41,268, 2.6 times the $15,882 reported in 2019. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $156.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- Madrigal Pharmaceuticals$31K
- Ironwood Pharmaceuticals, Inc$2K
- Phathom Pharmaceuticals, Inc.$1K
- Johnson & Johnson$742
- Bristol Myers Squibb$660
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$74,74489%
- Travel & lodging$2440%
- Food & beverage$8,58110%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 268 | $44,996 |
| Madrigal Pharmaceuticals | 26 | $31,168 |
| Ironwood Pharmaceuticals, Inc | 7 | $2,419 |
| Phathom Pharmaceuticals, Inc. | 8 | $1,138 |
| Johnson & Johnson(2 entities) | 50 | $742 |
| Bristol Myers Squibb | 38 | $660 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $514 |
| Ardelyx, Inc. | 16 | $419 |
| Pfizer | 20 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $259 |
| Gilead | 12 | $232 |
| Vertex | 1 | $113 |
| QOL Medical, LLC | 4 | $89 |
| Intercept Pharmaceuticals, Inc. | 6 | $83 |
| Intuitive Surgical | 1 | $69 |
| Sanofi | 2 | $64 |
| Covidien LP | 1 | $61 |
| Nestle Healthcare Nutrition Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $47 |
| Redhill Biopharma Inc. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 2 | $37 |
| Novo Nordisk | 2 | $32 |
| Ambu Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Acera Surgical, Inc. | 1 | $13 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,730 in reported general payments places this provider in the 90th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 18 | $115,135 |
| ZenpepLipase/Protease/Amylase | 12 | $65,143 |
| RezdiffraResmetirom | 11 | $45,488 |
| LinzessLinaclotide | 45 | $42,580 |
| XifaxanRifaximin | 14 | $41,592 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 201 | $33,802 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 204 | $3,275 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 168 | $2,375 |
| Pantoprazole Sodium | 238 | $2,294 |
| Sucralfate | 53 | $1,722 |
| Budesonide DrBudesonide | 11 | $1,364 |
| Dicyclomine Hcl | 72 | $1,033 |
| CholestyramineCholestyramine (With Sugar) | 13 | $802 |
| Omeprazole | 59 | $784 |
| Lactulose | 11 | $680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $37 | $65,14312 claims |
| Madrigal PharmaceuticalsRezdiffra | $31,168 | $45,48811 claims |
| AbbVieLinzess | $44,996 | $42,58045 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $514 | $41,59214 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $26 | $33,802201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Lake Charles
- Nisha PatelLake Charles$12K
- Ricardo McCallLake Charles$11K
- Sarpreet BasraLake Charles$10K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.